Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Published Time:
2021-03-12 17:39
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
IBD encompasses chronic, non-specific inflammatory conditions of the gut, primarily ulcerative colitis (UC) and Crohn's disease (CD). Clinical manifestations include diarrhea, abdominal pain, and even bloody stools. UC can occur at any age, with peaks between 15-30 and 50-70 years old. It primarily affects the rectum and sigmoid colon, exhibiting diffuse distribution. CD can also occur at any age but is most common in adolescence. Lesions can affect the entire gastrointestinal tract from mouth to anus, characterized by segmental and skip lesions, most frequently involving the terminal ileum, colon, or both the small and large intestine. Both UC and CD are chronic inflammatory diseases currently without a cure, requiring lifelong medication management. Often termed "incurable intestinal disorders," they carry high relapse rates of 70–90%. The incidence of IBD in China is steadily increasing, establishing it as a common and challenging condition within the digestive system. It represents a key focus and significant challenge in both basic research and clinical diagnosis/treatment of digestive diseases.
Janus kinases (JAKs) comprise a family of tyrosine kinases, consisting of four members: JAK1, JAK2, JAK3, and TYK2. JAKs play crucial roles in signal transduction for numerous cytokines. Together with their downstream effectors, Signal Transducers and Activators of Transcription (STATs), they mediate cytokine receptor regulation of nuclear gene transcription and expression. Dysfunction of the JAK-STAT signaling pathway is closely associated with the pathogenesis of hematological diseases such as polycythemia vera, thrombocythemia, leukemia, and myelofibrosis, as well as autoimmune disorders including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), IBD, and atopic dermatitis. Consequently, the JAK kinase family has emerged as a critical therapeutic target for these conditions.
About VC005
VC005 is a novel, potent, gut-restricted selective JAK1 inhibitor independently developed by Jiangsu Vcare. It features controllable systemic exposure coupled with high intestinal exposure. Preclinical studies have demonstrated that VC005 exhibits a low effective dose, high tolerated dose, and minimal side effects in animal models, offering dual advantages of safety and efficacy. It holds promise as a potential globally leading gut-selective anti-inflammatory drug.
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn